Related Experiment Video
Updated: May 30, 2026

Preparation of Adipose Progenitor Cells from Mouse Epididymal Adipose Tissues
Published on: August 25, 2020
Adipocytokines: The pied pipers
Hardik Gandhi1, Aman Upaganlawar, R Balaraman
1Department of Pharmacy, Faculty of Technology and Engineering, The M. S. University of Baroda, Vadodara - 390 001, Gujarat, India.
Abstract:
Even though there have been major advances in therapy, atherosclerosis and coronary artery disease retain their lead as one of the major causes of morbidity and mortality in the first decade of 21(st) century. To add to the woes, we have diabetes, obesity and insulin resistance as the other causes. The adipose tissue secretes several bioactive mediators that influence inflammation, insulin resistance, diabetes, atherosclerosis and several other pathologic states besides the regulation of body weight. These mediators are mostly proteins and are termed "adipocytokines". Adiponectin, resistin, visfatin, retinol binding protein-4 (RBP-4) and leptin are a few such proteins. Adiponectin is a multimeric protein, acting via its identified receptors, AdipoR1 and AdipoR2. It is a potential biomarker for metabolic syndrome and has several antiinflammatory actions. Adiponectin increases insulin sensitivity and ameliorates obesity. Resistin, another protein secreted by the adipose tissue, derived its name due to its involvement in the development of insulin resistance. It plays a role in the pathophysiology of several conditions because of its robust proinflammatory activity mediated through the activation of extracellular signal regulated kinases 1 and 2 (ERK 1/2). In 2007, resistin was reported to have protective effect in ischemia-reperfusion injury and myocyte-apoptosis in the setting of myocardial infarction (MI). RBP-4 is involved in the developmental pathology of type 2 diabetes mellitus and obesity. Visfatin has been described as an inflammatory cytokine. Increased expression of visfatin mRNA has been observed in inflammatory conditions like atherosclerosis and inflammatory bowel disease. Leptin mainly regulates the food intake and energy homeostasis. Leptin resistance has been associated with development of obesity and insulin resistance. Few drugs (thiazolidinediones, rimonabant, statins, etc.) and some lifestyle modifications have been found to improve the levels of adipocytokines. Their role in therapy has a lot in store to be explored upon.
Insights
Adipose tissue secretes adipocytokines like adiponectin and resistin, influencing inflammation, insulin resistance, and obesity. Therapies targeting these adipocytokines show promise for treating metabolic and cardiovascular diseases.
Area of Science:
- Biochemistry
- Endocrinology
- Cardiovascular Medicine
Background:
- Atherosclerosis and coronary artery disease remain leading causes of mortality.
- Diabetes, obesity, and insulin resistance are significant co-morbidities.
- Adipose tissue releases bioactive proteins called adipocytokines that impact metabolic and inflammatory processes.
Purpose of the Study:
- To review the role of key adipocytokines in metabolic and cardiovascular diseases.
- To highlight the involvement of adiponectin, resistin, RBP-4, visfatin, and leptin.
- To discuss potential therapeutic implications of modulating adipocytokine levels.
Main Methods:
- Literature review of adipocytokines and their associated pathologies.
- Analysis of the molecular mechanisms of adipocytokines like adiponectin and resistin.
- Examination of the link between adipocytokines and conditions such as insulin resistance, obesity, and atherosclerosis.
Main Results:
- Adiponectin exhibits anti-inflammatory actions, enhances insulin sensitivity, and ameliorates obesity.
- Resistin promotes inflammation and is implicated in insulin resistance and myocardial infarction pathophysiology.
- RBP-4 is linked to type 2 diabetes and obesity; visfatin is an inflammatory cytokine; leptin regulates energy homeostasis but leptin resistance contributes to obesity.
Conclusions:
- Adipocytokines play a crucial role in the pathogenesis of metabolic and cardiovascular diseases.
- Modulating adipocytokine levels through drugs or lifestyle changes may offer therapeutic benefits.
- Further research is needed to fully explore the therapeutic potential of targeting adipocytokines.

